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LETTERS TO THE EDITOR
Reliability of Transfer
Functions in Determining Central
Pulse Pressure and Augmentation Index
We read with interest the study by Wilkinson et al. (1) in the
March 20, 2002, issue of JACC. The investigators employed pulse
wave analysis using sphygmorCor software (AtCor Medical, Syd-
ney, Australia) for the derivation of central aortic waveforms from
radial waveforms acquired by applanation tonometry, and they
presented data on the derived aortic pulse pressure and augmentation
index. The findings of the study are as expected; however, we are
concerned that the technique described is being increasingly utilized,
but remains poorly validated in the literature. The researchers state
that the technique utilizes a “validated transfer function,” yet this
assertion is not supported by the references they quote (2–5).
Karamanoglu et al. (2) derived a transfer function by frequency
domain analysis of central aortic and applanation tonometry-
acquired radial waveforms in 14 patients. They report systolic
pressure alone without prospective validation. Takazawa et al. (4)
applied the transfer function of Karamanoglu et al. (2) to an
additional small cohort and found an 11 mm Hg discrepancy
between measured and derived central aortic pressures, when
tonometry-acquired pressures were calibrated to noninvasive brachial
pressures, suggesting that this transfer function may not be general-
izable to other subjects. These investigators also found the transfer
function to underestimate central augmentation index on average,
with considerable individual variability that was not quantified.
Segers et al. (5) applied the transfer function of Chen et al. (6),
derived by a time domain, rather than a frequency domain,
analysis. There may be important differences between transfer
functions derived by frequency and time domain analyses in their
ability to reconstruct central waveforms accurately, with potential
advantages to the latter (7). Segers et al. (5) found wide individual
variability in derived aortic augmentation index, with Bland-
Altman 95% limits of agreement of approximately 30%. These
findings support those of Fetics et al. (7), using a different transfer
function derived by time domain analysis, who described a per-
centage error in augmentation index estimation of 54  232% in
19 patients, but very good estimation of central systolic pressure,
when tonometry-acquired pressures were calibrated to central
aortic mean and diastolic pressures. These findings are consistent
with the findings of Chen et al. (6) that augmentation index is
highly dependent upon high-frequency components of the wave-
form, and the frequency response characteristics of applanation
tonometry are such that high-frequency data is inevitably lost by
this technique (8). The proprietary transfer function of the
sphygomoCor software is unpublished, and it is unclear as to
whether it has been derived by either frequency or time domain
analysis. Pauca et al. (3) utilized the sphygmoCor software and
prospectively evaluated it for the derivation of central blood pressures
only, from invasively measured radial waveforms, when calibration of
peripheral waveforms was not required. These data cannot validate the
technique for use with noninvasively obtained radial waveforms.
We suggest that, although some transfer functions may ade-
quately reproduce central aortic pressures from radial waveforms
acquired by applanation tonometry, it is premature to suggest that
the technique is well validated for noninvasive use, and published
data suggest that the technique may be unreliable for the derivation
of central aortic augmentation index. This technique should be
properly validated before being applied to large-scale prospective
intervention studies.
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REPLY
We are pleased that Dr. Hope and colleagues enjoyed our study
demonstrating, for the first time, that hypercholesterolemia is
associated with increased central pressure and left ventricular load
(1). We welcome the opportunity to put to bed their previously
voiced concerns regarding the generalized transfer function. In-
deed, new devices and techniques can confuse busy clinicians, and,
therefore, this important issue deserves clarification.
We used a Millar tonometer (SPT-301; Houston, Texas),
identical to that used by one of the investigators in a study
published in the same issue of JACC (2). This device differs from
that used in two of the studies that Dr. Hope and colleagues cite
when questioning the use of a transfer function (references 4 and
8). Moreover, the accuracy of the Millar tonometer has been
confirmed in a series of 62 patients against intra-arterial manom-
eter systems with adequate and known frequency response (3).
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Difference in harmonic content was 0.4 mm Hg for the first
eight harmonics, which contained 99.9% of cumulative power.
Thus, the Millar tonometer provides a robust method for high-
fidelity recording of the important features of the radial waveform.
The generalized transfer function used in sphygmoCor is
virtually identical to that described by Lasance et al. (4), as well as
by Karamanoglu et al. (5), and its utility was described by Chen et
al. (6). Its validity has also been confirmed in a realistic model of
the human upper limb (7). When this generalized transfer function
was prospectively validated against invasively recorded aortic pres-
sures in a large group of patients, the mean offset for systolic,
diastolic, mean, and pulse pressures was 1 mm Hg (SD 4.5)
(8). Differences were slightly greater (mean 4 mm Hg, SD 7)
for augmented and end-systolic pressures (9) but still within the
Association for the Advancement of Medical Instrumentation
(AAMI) SP10 criteria for “substantial equivalence.” Therefore, we
believe that the validity of the transfer function itself is proven, and
we understand that the Food and Drug Administration (FDA) has
accepted use of the sphygmoCor system when combined with
accurate intra-arterial manometer systems, and with the noninva-
sive Millar tonometer. Nevertheless, we have retrospectively com-
pared augmentation index in the radial artery between the two
groups in our original study (1). Radial augmentation was en-
hanced in the hypercholesterolemic subjects (66 vs. 78%; p 
0.001), suggesting that the observed differences in central augmen-
tation were not due to the transfer function per se. Rather, the
transfer function permits accurate, noninvasive determination of
central pressures and thus left ventricular load.
Finally, Dr. Hope and colleagues question cuff calibration of
peripheral waveforms. Although we agree that invasive radial
waveforms were used in the most recent validation study (8), such
an approach tests the validity of the transfer function itself. We
also accept that not all automated sphygmomanometers are accu-
rate. However, we used a device that meets both the British
Hypertension Society and AAMI standards (Omron, 705CP),
thus minimizing any potential source of error (10). The investi-
gators should remember that such scaling issues also apply to other
techniques—for example, when carotid waveforms are scaled to
pressures recorded by sphygmomanometry in the arm (2,11).
Moreover, such investigators have not always used validated
devices (12). We trust we have put to rest the concerns voiced by
Dr. Hope and colleagues about the transfer function, and we await
with interest the results of the large-scale outcome studies using
sphygmoCor currently in progress, as we are sure they do too.
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Enoxaparin After
High-Risk Coronary Stenting
We read with interest the report by Batchelor et al. (1), published
in the November 15, 2001, issue of the Journal. They conclude
that, given the relative safety of enoxaparin and the potential to
reduce the risk of subsequent infarction, a 14-day course of
enoxaparin may be considered for carefully selected patients. We
would like to comment on some aspects of their study.
The investigators’ conclusion is based on the finding of a
reduction of myocardial infarction at 30 days. This variable was
neither the primary end point nor a predefined secondary end
point in their study. The fact that the study was stopped prema-
turely owing to a low rate of events does not, in our opinion, allow
one to conclude a therapeutic recommendation. Of course, it is
possible that the end point was not achieved because of a beta
error, as pointed out by the researchers, but we do not know what
the outcome would be in a study including at least 3,590 patients,
which was the recalculated sample size. Contrarily, Batchelor et al.
(1) affirm that rates of major bleeding (3.3% for enoxaparin, 1.6%
for placebo, p  0.08) were comparable. In reality, the rate of this
event with enoxaparin was two times higher than with placebo,
and the p value was next to the conventionally accepted signifi-
cance level. In this case, the lack of statistical significance could
also be due to a beta error, but this is omitted by the investigators.
Some aspects of the discussion deserve comment. It is men-
tioned that enoxaparin’s clinical superiority over unfractionated
heparin (UFH) has been shown in patients with acute coronary
syndromes (2–4) and that extended low-molecular-weight hepa-
rins (LMWHs) also reduce the short-term risk of thrombotic
events, although benefits are not sustained at six months (5). In the
same manner that it is mentioned that enoxaparin was superior to
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